Exclusive Summary

• With all original patents long expired, this WHO Essential Medicine is the first-line "gold standard" for bipolar disorder, completely free from IP risks.
• Approximately 40 million patients globally require lifelong treatment; the 0.25g dose is optimal for titration, guaranteeing massive and highly inelastic market demand.
• Frequent drug shortages in the US, Europe, and LATAM due to supply chain fragilities make "reliable and uninterrupted supply" a highly attractive selling point for global distributors.
• Leveraging China's absolute dominance in lithium processing and an integrated API-to-FDF supply chain, it offers unparalleled cost economies and lucrative profit margins for overseas partners.